ClinicalTrials.gg
RecruitingNCT07874620Updated Oct 23, 2026

A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain

A Phase 2 interventional study of Cebranopadol and Cebranopadol in Chronic Pain, Pain and Opioid Withdrawal (Disorder), sponsored by Adneuris Therapeutics, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Adneuris Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 23, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,283 studies in Chronic Pain with a site in United States — 258 open to participants now, 349 under way, 7 of them phase 3. Chronic Pain · United States.

Planned enrollment
626th of 1,092
45 · median 60
Started
2026
with 66 others
Phase 2
87 of 1,283
19 open now
Primary completion
2027-03
later than 160 of 348 live
Registered
1,280th of 1,283
by date

Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 626th largest by planned enrollment of the 1,092 interventional ones that give a count, is one of 67 that started in 2026, is one of 87 in phase 2, reaches primary completion later than 160 of the 348 other live ones, and was the 1,280th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

258 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:

252 more — sign in →

All 258 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,283 studies in Chronic Pain with a site in United States, or all of them as a file.
02

Study summary

This Phase 2 study will evaluate whether multiple doses of cebranopadol suppress opioid withdrawal signs and symptoms compared with placebo in adults with chronic pain who are physically dependent on prescribed opioids. Participants whose physical dependence is confirmed will be assigned by chance to one of two cebranopadol dose regimens or matching placebo. The study will also evaluate pain, safety and tolerability, and cebranopadol pharmacokinetics.

Read the detailed description

Participants will complete outpatient screening followed by an inpatient treatment period and a safety follow-up telephone call. Within 30 days of initiating screening, participants will be admitted to the clinical research site.

Their current prescribed opioid will be withheld after the scheduled morning dose on Day -1, and withdrawal signs and symptoms will be assessed using the Clinical Opiate Withdrawal Scale (COWS) and Subjective Opioid Withdrawal Scale (SOWS) to confirm physical dependence. Participants meeting the predefined withdrawal criteria will resume their prescribed opioid as specified in the protocol and will subsequently be randomized on Day 1. Eligible participants will be randomized 1:1:1, stratified by current prescribed daily opioid regimen (50-75 morphine milligram equivalents [MME] versus >=76 MME), to cebranopadol 400 micrograms in the morning plus 200 micrograms in the evening, cebranopadol 400 micrograms twice daily, or matching placebo twice daily. Study drug is administered every 12 hours for 48 hours. Participants remain inpatient during treatment and undergo withdrawal, pain, safety, and pharmacokinetic assessments. Rescue medication is available according to protocol-defined criteria. Participants may resume their current prescribed opioid at least 12 hours after the final study-drug dose and are monitored until discharge on Day 4. A safety follow-up telephone call occurs on Day 7 (+/-2 days) after the last study-drug administration

03

Conditions studied

  • Chronic Pain
  • Pain
  • Opioid Withdrawal (Disorder)
  • Opioid Use Disorder

Keywords

  • cebranopadol
  • opioid withdrawal;
  • physical dependence;
  • chronic pain;
  • Clinical Opiate Withdrawal Scale
  • COWS
  • Subjective Opioid Withdrawal Scale
  • SOWS Opioid use disorder
  • Subject Opioid Withdrawal scale
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adults 18-65 years with 18.0-40.0 kg/m² and weight ≥50 kg.
  • Chronic daily pain for ≥6 months due to chronic low back pain, hip/knee osteoarthritis, or painful peripheral neuropathy.
  • Prescribed opioid use ≥5 days/week for ≥3 months within the prior 6 months, generally 50-90 MME/day; >90 MME/day may be allowed with Sponsor/designee approval.
  • Generally in good health and able to comply with study procedures, including opioid withdrawal and inpatient confinement.
  • Meet protocol-specified reproductive and requirements.
  • Able to provide and complete study assessments in English.
  • Physical opioid dependence confirmed by protocol-defined COWS and/or SOWS criteria before randomization.

Key Exclusion Criteria:

  • medical or psychiatric condition that could compromise participant safety or study validity.
  • Protocol-specified excluded pain, neurologic, spinal, infectious, or neoplasm-related conditions.
  • >450 ms in males or >470 ms in females, other torsade de pointes risk factors, or use of QT-prolonging medications.
  • Substance use disorder other than opioid, nicotine, or caffeine use disorder, or positive testing for prohibited drugs/alcohol, subject to the protocol-specified cannabinoid exception.
  • Positive , surface antigen, or antibody test.
  • Suicidal ideation or active suicidality within the past 2 years.
  • Use of prohibited medications or inability to meet protocol-specified medication washout requirements.
  • Pregnant or breastfeeding or planning pregnancy within 30 days after the last study-drug dose.
  • Significant adverse reaction to naloxone or related opioids/opioid antagonists.
  • Unable to undergo IV catheter placement or otherwise considered unsuitable or unlikely to comply with the protocol.
  • Legal, employment, or other circumstances that could interfere with study participation or compliance.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Cebranopadol 600 micrograms/day

    Cebranopadol 400 micrograms orally in the morning and 200 micrograms orally in the evening on Day 1 and 2; final dose on the evening of Day 2

    Drug: Cebranopadol

  • Experimental
    Cebranopadol 800 micrograms/day

    Cebranopadol 400 micrograms orally twice daily on Day 1 and 2; Final dose on the evening of Day 2.

    Drug: Cebranopadol

  • Placebo comparator
    Placebo Comparator

    Matching placebo orally twice daily on Day 1 and 2 days; Final dose on the evening of Day 2.

    Drug: Placebo

Interventions

  • Administration orally twice daily on Days 1 and 2 and according to the assigned regimen.

  • Administration orally twice daily on Days 1 and 2 and according to the assigned regimen.

  • DrugPlacebo

    Administration orally twice daily on Day 1 and 2.

06

What researchers measure

Primary outcomes

  1. Clinical Opiate Withdrawal Scale (COWS) Total Score Maximum Effect (Emax) from 0 to 48 hours

    Maximum (peak) COWS total score observed during the 48-hour assessment period. after the first study drug dose, using the protocol-specified adjustment for rescue medication. The COWS is an 11-item clinician-rated scale used to assess opioid withdrawal signs and symptoms. Total scores range from 0 to 48, with higher scores indicating greater withdrawal severity.

    Time frame: From first study-drug administration through 48 hours after the first dose]

Secondary outcomes

  1. Area under the curve of COWS Total Score from 0 to 48 hours (AUC0-48)

    Area under the curve (AUC) of COWS total score-time curve from 0 to 48 hours after the first study drug dose, using the protocol-specified adjustment for rescue medication. COWS total scores range from 0 to 48, with higher scores indicating greater withdrawal severity.

    Time frame: From first study-drug administration through 48 hours after the first dose.

  2. Proportion of Participants Meeting the COWS Responder Criteria

    Proportion of participants meeting the protocol-defined COWS responder criteria based on average COWS total score and absence of opioid rescue medication through 24 hours. A responder is defined as having at least 30 percent improvement and/or a COWS total score of 5 or less and/or transition to a lower withdrawal severity category from baseline, without opioid rescue medication through 24 hours.

    Time frame: From first study-drug administration through 24 hours after the first dose

  3. Maximum Change From Baseline in COWS Total Score by Dosing Day.

    Maximum change from baseline in COWS total score by dosing day during Day 1, Day 2.

    Time frame: Baseline- From first study-drug administration through 72 hours after the first dose

  4. Area Under the Curve of COWS Total Score From 0 to 24 Hours (AUC0-24) COWS Total Score AUC0-24and From 0 to 72 Hours (AUC0-72).

    Area under the curve (AUC) of COWS total scores, through 24 hours; and 72 hours after the first study drug dose, using the protocol-specified adjustment for rescue medication.

    Time frame: 0-24 hours and 0-72 hours after first study-drug administration

  5. Maximum Subjective Opioid Withdrawal Scale (SOWS) Total Score.

    Subjective Opioid Withdrawal Scale total score assessed using Emax, maximum change from baseline by dosing day, and area-under-the-curve summaries. The SOWS is a participant-reported measure of opioid withdrawal symptoms. Total scores range from 0 to 64, with higher scores indicating greater withdrawal severity.

    Time frame: Through 72 hours after first study-drug administration]

  6. Participants Receiving Rescue Medication

    Proportion of participants who receive protocol-permitted rescue medication for withdrawal signs and symptoms.

    Time frame: Through the inpatient assessment period, up to 72 hours after first study-drug administration

  7. Time to First Rescue Medication for Withdrawal

    Time from first study-drug administration to first administration of protocol permitted rescue medication to manage withdrawal symptoms

    Time frame: Up to 72 hours after first study-drug administration

  8. Opioid Rescue Medication Use

    Number of opioid rescue medication doses and total opioid rescue medication use expressed in morphine milligram equivalents (MME).

    Time frame: Up to 72 hours after first study-drug administration]

  9. Area Under the Curve of "Pain Right Now" Numeric Pain Rating Scale Score From 0 to 48 Hours (AUC0-48)

    Area under the curve for of "Pain Right Now" Numerical Pain Rating Scale (NPRS) pain 'right now' scores from 0 to 48 hours after the first study drug dose, using the protocol-specified adjustment for rescue medication. NPRS scores range from 0 (no pain) to 10 (worst possible pain).

    Time frame: 0 to 48 hours after first study-drug administration

  10. Proportion of Participants With at Least a 2-Point Improvement from Baseline in Average 24-Hour Pain.

    Percentage of participants with at least a 2-point improvement from baseline in the NPRS rating of average pain during the previous 24 hours.

    Time frame: 0 to 72 hours after first study-drug administration

  11. Change From Baseline in Average/Worst/Least Pain During the Previous 24 Hours

    Change from baseline in participant-reported Average/Worst/Least pain during the previous 24 hours on NPRS.

    Time frame: 0 to 72 hours after first study drug administration

  12. Non-Opioid Rescue Medication Use

    Number of non-opioid rescue medication doses and total non-opioid rescue medication use summarized by medication type.

    Time frame: Up to 72 hours after first study-drug administration]

07

Study locations

2 of 2 sites recruiting
  • 001127
    North Canton, Ohio 44702, United States
    Recruiting
  • 00113
    Houston, Texas 77043, United States
    Recruiting
08

References and documents

Publications

  • Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP. Validity of four pain intensity rating scales. Pain. 2011 Oct;152(10):2399-2404. doi: 10.1016/j.pain.2011.07.005. PubMed 21856077 ↗
  • Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kaasa S; European Palliative Care Research Collaborative (EPCRC). Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011 Jun;41(6):1073-93. doi: 10.1016/j.jpainsymman.2010.08.016. PubMed 21621130 ↗
  • Lofwall MR, Walsh SL, Bigelow GE, Strain EC. Modest opioid withdrawal suppression efficacy of oral tramadol in humans. Psychopharmacology (Berl). 2007 Oct;194(3):381-93. doi: 10.1007/s00213-007-0847-3. Epub 2007 Jul 1. PubMed 17605004 ↗
  • Lofwall MR, Babalonis S, Nuzzo PA, Elayi SC, Walsh SL. Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug Alcohol Depend. 2016 Jul 1;164:143-150. doi: 10.1016/j.drugalcdep.2016.05.002. Epub 2016 May 10. PubMed 27234658 ↗
  • Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction. 2004 Nov;99(11):1439-49. doi: 10.1111/j.1360-0443.2004.00834.x. PubMed 15500597 ↗
  • Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003 Apr-Jun;35(2):253-9. doi: 10.1080/02791072.2003.10400007. PubMed 12924748 ↗
09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.

Of 60 phase 2 interventional studies under Chronic Pain, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 52. This study's planned 5 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2026
First posted
Oct 15, 2026
StartEst.
Oct 2026was Sep 2026
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 23, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • 001127 · North Canton, United Statesno status→Recruiting
  • 00113 · Houston, United Statesno status→Recruiting
Oct 23, 2026
Start date
Sep 2026→Oct 2026
Oct 23, 2026
Registered
First appeared on the registry
Oct 15, 2026
Show all 3 updates
  1. Oct 23, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • 001127 · North Canton, United Statesno status→Recruiting
    • 00113 · Houston, United Statesno status→Recruiting
    Start date Sep 2026→Oct 2026
  2. Oct 19, 2026
    Minor edits only
    + 2 other changes: index terms and conditions
  3. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07874620
Lead sponsor
Adneuris Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Oct 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Study Director Adneuris Therapeutics
Contact
clinicaltrials@trispharma.com
732-940-2800
Clinical Development Adneuris Therapeutics
Contact
clinicaltrials@trispharma.com
732-940-2800
Khyati Mehta
study director · Adneuris Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion